文献速递肝病

PBC失代偿肝硬化患者潜在肝脏再代偿标准的评估

Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2024-02-26

该回顾性研究纳入42例首次失代偿的PBC肝硬化患者,探索UDCA生化应答(Paris-II标准)作为病因治疗替代指标下的再代偿可能。7例(16.7%)实现再代偿,再代偿与较低MELD-Na、胆红素、ALP及静脉曲张出血事件相关;UDCA应答者再代偿率41.7%高于无应答者9.5%。再代偿后仍可发生肝脏相关并发症,需密切随访。

要点

  • PBC失代偿肝硬化患者经UDCA治疗可能实现肝脏再代偿,本队列再代偿率为16.7%。
  • UDCA应答(Paris-II标准)者再代偿率41.7%,无应答者9.5%。
  • 再代偿后仍可出现肝脏恶性肿瘤和/或门静脉血栓等并发症,需密切随访。

核心结论

  • PBC失代偿肝硬化患者在UDCA治疗下可能实现肝脏再代偿。
  • 再代偿后仍可发生肝脏相关并发症,患者应保持密切随访。

研究设计与样本

  • 回顾性纳入首次失代偿的PBC肝硬化患者42例,年龄63.5(IQR 51.9-69.2)岁,女性88.1%,MELD-Na 13.5(IQR 11.0-15.0)。
  • 失代偿后随访41.9(IQR 11.0-70.9)个月。
  • 再代偿定义为腹水和肝性脑病缓解且停用利尿/HE治疗、无静脉曲张出血及持续肝功能改善。

主要发现

  • 7例(16.7%)实现再代偿。
  • 再代偿与较低MELD-Na(SHR 0.90;p=0.047)、较低胆红素(SHR每mg/dL 0.44;p=0.005)和较低ALP(SHR每10 U/L 0.67;p=0.001)相关。
  • 静脉曲张出血作为失代偿事件与再代偿概率相关(SHR 4.37;p=0.069)。
  • 33例UDCA治疗≥1年,12例(36%)达到Paris-II应答标准;应答者再代偿5/12(41.7%),无应答者2/21(9.5%)。
  • 再代偿与无移植生存数值上改善相关(HR 0.46;p=0.335)。

关键数值与推荐

  • UDCA生化应答采用Paris-II标准作为成功病因治疗的替代指标。
  • 再代偿定义包括腹水和HE缓解且停用相应治疗、无静脉曲张出血及持续肝功能改善。

临床怎么用

  • 对PBC失代偿肝硬化患者,UDCA治疗下可评估再代偿可能。
  • UDCA应答(Paris-II标准)与更高再代偿概率相关,可作为评估参考。
  • 再代偿后仍需密切随访,警惕肝脏恶性肿瘤和门静脉血栓等并发症。

局限性

  • 回顾性研究设计。
  • 样本量较小(42例)。
  • 再代偿与无移植生存关联的p值未达统计学显著性(p=0.335)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aetiological therapy improves liver function and may enable hepatic recompensation in decompensated cirrhosis. AIMS: We explored the potential for recompensation in patients with decompensated primary biliary cholangitis (PBC) - considering a biochemical response to ursodeoxycholic acid (UDCA) according to Paris-II criteria as a surrogate for successful aetiological treatment. METHODS: Patients with PBC were retrospectively included at the time of first decompensation. Recompensation was defined as (i) resolution of ascites and hepatic encephalopathy (HE) despite discontinuation of diuretic/HE therapy, (ii) absence of variceal bleeding and (iii) sustained liver function improvement. RESULTS: In total, 42 patients with PBC with decompensated cirrhosis (age: 63.5 [IQR: 51.9-69.2] years; 88.1% female; MELD-Na: 13.5 [IQR: 11.0-15.0]) were included and followed for 41.9 (IQR: 11.0-70.9) months after decompensation. Seven patients (16.7%) achieved recompensation. Lower MELD-Na (subdistribution hazard ratio [SHR]: 0.90; p = 0.047), bilirubin (SHR per mg/dL: 0.44; p = 0.005) and alkaline phosphatase (SHR per 10 U/L: 0.67; p = 0.001) at decompensation, as well as variceal bleeding as decompensating event (SHR: 4.37; p = 0.069), were linked to a higher probability of recompensation. Overall, 33 patients were treated with UDCA for ≥1 year and 12 (36%) achieved Paris-II response criteria. Recompensation occurred in 5/12 (41.7%) and in 2/21 (9.5%) patients with vs. without UDCA response at 1 year, respectively. Recompensation was linked to a numerically improved transplant-free survival (HR: 0.46; p = 0.335). Nonetheless, 4/7 recompensated patients presented with liver-related complications after developing hepatic malignancy and/or portal vein thrombosis and 2 eventually died. CONCLUSIONS: Patients with PBC and decompensated cirrhosis may achieve hepatic recompensation under UDCA therapy. However, since liver-related complications still occur after recompensation, patients should remain under close follow-up.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hofer BS, Burghart L, Halilbasic E, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther. 2024. PMID: 38409879. doi:10.1111/apt.17908

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。